Trial Profile

A Phase 1 Clinical Study to Investigate the Safety and Pharmacokinetics of MK-5684 in China Participants With Metastatic Castration-Resistant Prostate Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 27 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dexamethasone (Primary) ; Fludrocortisone (Primary) ; Opevesostat (Primary) ; Hydrocortisone
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions; Pharmacokinetics
Acronyms MK-5684-001
Sponsors Merck Sharp & Dohme

Most Recent Events

22 Oct 2025 Planned primary completion date changed from 30 Sep 2025 to 14 Nov 2025.
21 Aug 2024 Planned End Date changed from 14 Oct 2027 to 14 Mar 2027.
21 Aug 2024 Planned primary completion date changed from 30 Apr 2026 to 30 Sep 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com